Michael White
Angel Investor @ Silicon Valley Bank
San Diego, United States
Michael White is a National Head of Business Development and Managing Director for Silicon Valley Bank.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Michael White invests in
Stages Michael White invests in
Countries Michael White invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (75%)
- Pharmaceutical 3 (75%)
- Therapeutics 2 (50%)
- Medical 1 (25%)
- Biopharma 1 (25%)
Stage
- Debt Financing 3 (75%)
- Post-IPO Debt 1 (25%)
Country
- United States 3 (75%)
- United Kingdom 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmetmedical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs. | $40M / Debt Financing / Dec 21, 2022 | ||
| Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphoma. Viracta is pursuing application ofthis inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers. | $50M / Post-IPO Debt / Nov 05, 2021 | ||
| Numan is a startup which aims to tackle your tackle problem erectile dysfunction. | $26.8M / Debt Financing | ||
| At Zogenix, our core strategy is to develop and commercialize differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. We are a specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatmentof central nervous system disorders and pain. Our lead product candidate, sumatriptan DosePro™, enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine. Our second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. | Debt Financing |
Co-Investors
About Silicon Valley Bank
Silicon Valley Bank works with technology, life science, cleantech, venture capital, private equity, and premium wine businesses. SVB provides industry knowledge and connections, financing, treasury management, corporate investment, and international banking services to its clients worldwide through 27 U.S. offices and seven internationaloperations. Banking innovative companies and exclusive wineries, Silicon Valley Bank’s diverse financial services, knowledge, global network, and world-class service increase its clients’ probability of success. Forbes Magazine ranks SVB among America’s Best Banks, and Fortune Magazine named SVB one of the Best Companies to Work For in 2012.
Silicon Valley Bank Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dennis Grunt
Director
|
|||
Keith Cox
Head of Sponsor and Leveraged Finance
|
|||
Laura Scott
Managing Director
|
|||
Nicole Hawkey
Director
|
|||
Rochelle Stewart
Director, New & Strategic Channels
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Michael White invest in?
Michael White invests primarily in Biotechnology, Pharmaceutical and Therapeutics startups, most often at Debt Financing and Post-IPO Debt stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Michael White?
Public channels for Michael White include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Michael White last invest?
The most recent investment recorded for Michael White closed in Dec 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
